Predictive Oncology (FRA:S1K) Net Income From Continuing Operations : €-13.65 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Predictive Oncology's net income from continuing operations for the three months ended in Mar. 2024 was €-3.88 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-13.65 Mil.

Predictive Oncology Net Income From Continuing Operations Historical Data

The historical data trend for Predictive Oncology's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Net Income From Continuing Operations Chart

Predictive Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-17.45

-21.28

-17.40

-24.30

-12.82

Predictive Oncology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-3.20	-3.62	-2.96	-3.19	-3.88

Predictive Oncology Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.65 Mil.

Predictive Oncology (FRA:S1K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

POAI:USA

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines